

**MHRA**  
10 South Colonnade  
Canary Wharf  
London  
E14 4PU  
United Kingdom

[gov.uk/mhra](https://www.gov.uk/mhra)

## **Decision Cover Letter**

### **Decision of the licensing authority to:**

grant a product specific waiver

MHRA-100301-PIP03-23

### **Scope of the Application**

#### **Active Substance(s)**

nipocalimab

#### **Condition(s)**

Treatment of Sjögren's syndrome

#### **Pharmaceutical Form(s)**

Concentrate for solution for infusion, Solution for injection

#### **Route(s) of Administration**

INTRAVENOUS USE; SUBCUTANEOUS USE

#### **Name / Corporate name of the PIP applicant**

Janssen Cilag-Limited

#### **Basis for the Decision**

Pursuant to the Human Medicines Regulations 2012, Janssen Cilag-Limited submitted to the licensing authority on 28/04/2023 08:47 BST an application for a Waiver

The procedure started on 26/09/2023 08:54 BST

1. The licensing authority, having assessed the application in accordance with the Human Medicines Regulations 2012, decides, as set out in the appended summary report:

to grant a product specific waiver

2. The measures and timelines of the paediatric investigation plan are set out in the Annex I.

This decision is forwarded to the applicant, together with its annex and appendix.

**MHRA**  
10 South Colonnade  
Canary Wharf  
London  
E14 4PU  
United Kingdom

[gov.uk/mhra](http://gov.uk/mhra)

## Final Decision Letter

MHRA-100301-PIP03-23

Of 13/10/2023 10:42 BST

On the adopted decision for nipocalimab (MHRA-100301-PIP03-23) in accordance with the Human Medicines Regulations 2012.

The licensing authority, in accordance with the Human Medicines Regulations 2012, has adopted this decision:

Granting a waiver in all age groups for the listed condition(s)

This decision applies to a Waiver for nipocalimab, Concentrate for solution for infusion, Solution for injection , INTRAVENOUS USE SUBCUTANEOUS USE .

This decision is addressed to Janssen Cilag-Limited, 50-100 Holmers Farm Way, High Wycombe, UNITED KINGDOM, HP12 4EG

## ANNEX I

### 1. Waiver

#### 1.1 Condition:

Treatment of Sjögren's syndrome The waiver applies / applied to: Paediatric Subset(s): The paediatric population from birth to less than 18 years of age Pharmaceutical form(s): Concentrate for solution for infusion Solution for injection Route(s) of administration: INTRAVENOUS USE SUBCUTANEOUS USE Reason for granting waiver: For the paediatric population from birth to less than 2 years of age: on the grounds that the specific medicinal product is likely to be unsafe. For the paediatric population from 2 years to less than 18 years of age: on the grounds that the specific medicinal product does not represent a significant therapeutic benefit as clinical studies(s) are not feasible

### 2. Paediatric Investigation Plan:

#### 2.1 Condition(s):

Not applicable

**2.2 Indication(s) targeted by the PIP:**

Not applicable

**2.3 Subset(s) of the paediatric population concerned by the paediatric development:**

Not applicable

**2.4 Pharmaceutical Form(s):**

Not applicable

**2.5 Studies:**

<b>Study Type</b>	<b>Number of Studies</b>	<b>Study Description</b>
<b>Quality Measures</b>		
<b>Non-Clinical Studies</b>		
<b>Clinical Studies</b>		
<b>Extrapolation, Modeling &amp; Simulation Studies</b>		
<b>Other Studies</b>		
<b>Other Measures</b>		

**3. Follow-up, completion and deferral of a PIP:**

<b>Concerns on potential long term safety and efficacy issues in relation to paediatric use:</b>	
<b>Date of completion of the paediatric investigation plan:</b>	
<b>Deferral of one or more studies contained in the paediatric investigation plan:</b>	

